Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analys
- PDF / 651,895 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 110 Downloads / 228 Views
REVIEW
Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials K. Sansai 1,2 & M. Na Takuathung 1 & R. Khatsri 1 & S. Teekachunhatean 1,3 & N. Hanprasertpong 1 & N. Koonrungsesomboon 1,4 Received: 20 January 2020 / Accepted: 21 May 2020 # International Osteoporosis Foundation and National Osteoporosis Foundation 2020
Abstract Summary Isoflavones have a structure similar to 17β-estradiol, so they may be useful to postmenopausal women in preventing bone loss related to estrogen deficiency. The present study integrated the findings from 63 randomized controlled trials and found that isoflavone interventions may have benefits in the prevention and treatment of menopause-related osteoporosis. Purpose This study aimed to determine the efficacy of isoflavone interventions on bone density outcomes and the safety of isoflavone interventions in postmenopausal women by means of systematic review and meta-analysis. Methods A systematic search was performed on three databases (PubMed, Scopus, and Cochrane Library). Included studies were limited to randomized controlled trials (RCTs) assessing the effects of isoflavone intervention on bone mineral density (BMD) in postmenopausal women. Mean difference (MD) in BMD or relative risk for adverse outcomes was used as a summary effect measure; pooled-effect estimates were calculated using a random-effects model. Results A total of 63 RCTs, involving 6427 postmenopausal women, were included in the meta-analysis. Statistically significant differences in BMD at the last follow-up visit between the two groups (isoflavones vs. control) were found at the lumbar spine (MD = 21.34 mg/cm2, 95% CI = 8.21 to 34.47 mg/cm2, p = 0.001), the femoral neck (MD = 28.88 mg/cm2, 95% CI = 15.05 to 42.71 mg/cm2, p < 0.0001), and the distal radius (MD = 19.27 mg/cm2, 95% CI = 5.65 to 32.89 mg/cm2, p = 0.006). The positive effects in improved BMD were primarily associated with two formulations, i.e., genistein 54 mg/day and ipriflavone 600 mg/day. Isoflavone interventions were generally safe and well tolerated. Conclusion Isoflavone interventions, genistein (54 mg/day) and ipriflavone (600 mg/day) in particular, have beneficial effects on BMD outcomes and are safe in postmenopausal women. They may be considered as a complementary or alternative option in the prevention and treatment of menopause-related osteoporosis. Keywords Bone density . Genistein . Ipriflavone . Isoflavones . Osteoporosis . Postmenopausal women Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00198-020-05476-z) contains supplementary material, which is available to authorized users. * N. Koonrungsesomboon [email protected]; [email protected] 1
Department of Pharmacology, Faculty of Medicine, Chiang Mai University, 110 Intawaroros, Sriphoom, Muang, Chiang Mai 50200, Thailand
2
Master of Science Program in Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Data Loading...
